159 related articles for article (PubMed ID: 38619663)
21. [Minimal residual disease in adults with Philadelphia chromosome negative acute lymphoblastic leukemia in high-risk].
Li ZR; Zhao T; Liu YR; Wang YZ; Xu LP; Zhang XH; Wang Y; Jiang H; Chen YY; Chen H; Han W; Yan CH; Wang J; Jia JS; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):554-560. PubMed ID: 32397017
[No Abstract] [Full Text] [Related]
22. Characterization and prognostic implication of delayed complete response in AL amyloidosis.
Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Lisa Hwa Y; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Vincent Rajkumar S; Kyle RA; Dispenzieri A
Eur J Haematol; 2021 Mar; 106(3):354-361. PubMed ID: 33230879
[TBL] [Abstract][Full Text] [Related]
23. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
25. Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis.
Warsame R; LaPlant B; Kumar SK; Laumann K; Perez Burbano G; Buadi FK; Gertz MA; Kyle RA; Lacy MQ; Dingli D; Leung N; Hayman SR; Kapoor P; Hwa YL; Fonder A; Hobbs M; Gonsalves WI; Kourelis T; Lust J; Russell SJ; Zeldenrust S; Lin Y; Muchtar E; Go RS; Vincent Rajkumar S; Dispenzieri A
Blood Cancer J; 2020 Jan; 10(1):4. PubMed ID: 31913261
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.
Havasi A; Heybeli C; Leung N; Angel-Korman A; Sanchorawala V; Cohen O; Wechalekar A; Bridoux F; Jaffer I; Gutgarts V; Hassoun H; Levinson M; Rosenbaum C; Milani P; Palladini G; Merlini G; Hegenbart U; Schönland S; Veelken K; Pogrebinsky A; Doros G; Landau H
Blood Cancer J; 2022 Aug; 12(8):119. PubMed ID: 35982035
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemia.
Xiong W; Wang Z; Wang T; Yu Y; Huang Y; Sun H; Chen J; Lyu R; Wang H; Yan Y; Wang Q; Liu W; An G; Sui W; Huang W; Zou D; Xiao Z; Wang J; Ouyang G; Qiu L; Yi S
Front Immunol; 2023; 14():1171539. PubMed ID: 37234167
[TBL] [Abstract][Full Text] [Related]
28. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.
Avet-Loiseau H; Ludwig H; Landgren O; Paiva B; Morris C; Yang H; Zhou K; Ro S; Mateos MV
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):e30-e37. PubMed ID: 31780415
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Diamond B; Korde N; Lesokhin AM; Smith EL; Shah U; Mailankody S; Hultcrantz M; Hassoun H; Lu SX; Tan C; Rustad EH; Maura F; Maclachlan K; Peterson T; Derkach A; Devlin S; Landau HJ; Scordo M; Chung DJ; Shah GL; Lahoud O; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Giralt SA; Landgren O
Lancet Haematol; 2021 Jun; 8(6):e422-e432. PubMed ID: 34048681
[TBL] [Abstract][Full Text] [Related]
30. Association of minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A systemic literature review and meta-analysis.
Zhang W; Jang E
PLoS One; 2021; 16(8):e0256801. PubMed ID: 34437635
[TBL] [Abstract][Full Text] [Related]
31. The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis.
Angel-Korman A; Jaberi A; Sanchorawala V; Havasi A
Amyloid; 2020 Mar; 27(1):17-24. PubMed ID: 31595786
[No Abstract] [Full Text] [Related]
32. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
33. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
34. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
Tao Y; Jin S; Yang D; Pan M; Ouyang W; Liu Y; Wang Y; Zhang W; Mi J
BMC Cancer; 2024 Apr; 24(1):406. PubMed ID: 38565996
[TBL] [Abstract][Full Text] [Related]
35. The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis.
Liu B; Bai M; Wang Y; Wang D; Zhao J; Li L; Dong R; Sun S
Eur J Intern Med; 2019 Nov; 69():32-41. PubMed ID: 31447275
[TBL] [Abstract][Full Text] [Related]
36. Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
Bomsztyk J; Ravichandran S; Giles HV; Wright N; Berlanga O; Khwaja J; Mahmood S; Wisniowski B; Cohen O; Foard D; Gilbertson J; Rauf MU; Starr N; Martinez-Naharro A; Venneri L; Whelan C; Fontana M; Hawkins PN; Gillmore JD; Lachmann H; Harding S; Pratt G; Wechalekar AD
Blood; 2024 Mar; 143(13):1259-1268. PubMed ID: 38194690
[TBL] [Abstract][Full Text] [Related]
37. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
[No Abstract] [Full Text] [Related]
38. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis.
Molica S; Giannarelli D; Montserrat E
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):423-430. PubMed ID: 31027992
[TBL] [Abstract][Full Text] [Related]
39. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
[TBL] [Abstract][Full Text] [Related]
40. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute RM; Pawlyn C; Cairns DA; Davies FE; Menzies T; Rawstron A; Jones JR; Hockaday A; Henderson R; Cook G; Drayson MT; Jenner MW; Kaiser MF; Gregory WM; Morgan GJ; Jackson GH; Owen RG
J Clin Oncol; 2022 Sep; 40(25):2889-2900. PubMed ID: 35377708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
